University of Pennsylvania

Opus Genetics Announces Completion of Dosing in First Cohort of Phase 1/2 Trial of Gene Therapy OPGx-LCA5 in Patients with Rare Inherited Retinal Disease LCA5

Retrieved on: 
Tuesday, March 26, 2024
Opus, Retina, Leber congenital amaurosis, University of Pennsylvania, VR, Genetics, LCA5, University, Patient, Ophthalmology, LCA, Penn Presbyterian Medical Center, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C., March 26, 2024 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-first, clinical-stage gene therapy company developing treatments for inherited retinal diseases, today announced that the first cohort has completed dosing in its open-label, dose-escalation Phase 1/2 clinical trial evaluating the subretinal delivery of OPGx-LCA5, an adeno-associated virus 8 (AAV8) vector designed to precisely deliver a functional LCA5 gene to the outer retina in patients with Leber congenital amaurosis (LCA) resulting from biallelic mutations in the LCA5 gene (LCA5).

Key Points: 
  • Based on positive safety and efficacy data from the first cohort of three adult patients, the Company will advance OPGx-LCA5 into the next highest dose.
  • Opus anticipates initiating the next cohort mid-2024.
  • There are also future plans to expand the study population to include subjects 13 years or older.
  • “Based on these early clinical data, we’re excited for the potential of OPGx-LCA5 to transform the lives of patients affected by LCA5,” said Ben Yerxa, Ph.D., chief executive officer of Opus.

Chimerix Appoints Marc D. Kozin to Board of Directors

Retrieved on: 
Thursday, March 21, 2024
Growth, University of Pennsylvania, Shareholder, Patient, Duke University, Acquisition, University, Retirement, UFP Technologies, Economics, Management

DURHAM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the appointment of Marc D. Kozin as the newest member of the Company’s Board of Directors.

Key Points: 
  • DURHAM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the appointment of Marc D. Kozin as the newest member of the Company’s Board of Directors.
  • In addition, Patrick Machado has announced his retirement from the Chimerix Board effective at the Company’s 2024 Annual Meeting of Stockholders in June, after ten years of service.
  • “We are pleased to welcome Marc to the Board of Directors.
  • He currently serves on the Board of Directors of UFP Technologies (NASDAQ: UFPT) and HCRx Holdings.

Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer

Retrieved on: 
Monday, March 18, 2024
Neurology, University of Pennsylvania, Sarcoma, Cardiology, Ivy League, Protocol, University, Rheumatology, Dermatology, Infection, Harvard University, FSD, Melanoma, CMO, Vaccine, FDA, GU, Women's health, Yale University, Pharmaceutical industry

MALVERN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the appointment of Dr. Huma Qamar as Chief Medical Officer (CMO).

Key Points: 
  • MALVERN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the appointment of Dr. Huma Qamar as Chief Medical Officer (CMO).
  • “I’m very pleased to name Dr. Qamar as the CMO at Ocugen,” said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen.
  • Her expertise encompasses the development of Phase I-IV clinical protocols and execution of clinical studies, FDA inspections, and effective leadership of medical affairs teams.
  • “Dr.

Ten Oaks Group Expands Transaction Capabilities with Strategic New Additions

Retrieved on: 
Wednesday, April 3, 2024
Kyoto University, Partner, University of Pennsylvania, Goldman Sachs, Associate, University, TMT, MBA, Pennsylvania State University, Lead, Management

These strategic hires solidify Ten Oaks Group's position as a solution-driven buy-side partner, committed to delivering seamless carve-out transactions.

Key Points: 
  • These strategic hires solidify Ten Oaks Group's position as a solution-driven buy-side partner, committed to delivering seamless carve-out transactions.
  • Kyle McCormick is a Senior Associate at Ten Oaks Group.
  • Saika Maeda is a Japan Investment Lead at Ten Oaks Group.
  • Curtis Griner, Managing Partner of Ten Oaks Group, stated, "The additions of Kyle, Ethan, and Saika position Ten Oaks Group to capitalize on the opportunities we are witnessing in the carve-out market, providing a solution-oriented and streamlined process to our corporate partners both domestically and internationally."

Global Leaders in Cancer Research and Biotech Join The Mark Foundation for Cancer Research's Scientific Advisory and Industry Advisory Committees

Retrieved on: 
Tuesday, April 2, 2024
Molecule, Medicine, Cancer Research UK, FRS, Weill Cornell Medicine, Francis Crick Institute, B cell, Patient, Investment, Children's National Hospital, Therapy, Research, Biotechnology, Genentech, Dana–Farber Cancer Institute, Committee, Trial of the century, University, University College Hospital, Metastasis, Multiple sclerosis, Drug discovery, MBBS, Chairperson, MD, University College London, Senior, FRCP, University of California, Berkeley, Hospital, Nationwide Children's Hospital, Marker beacon, Diagnosis, Lung cancer, Ludwig Cancer Research, University of Pennsylvania, Doctor of Philosophy, BTK, GV (company), Celera Corporation, Pharmaceutical industry

NEW YORK, April 2, 2024 /PRNewswire/ -- The Mark Foundation for Cancer Research, a leading nonprofit dedicated to advancing research that transforms the prevention, diagnosis, and treatment of cancer, proudly announces the appointment of new members to its Scientific Advisory and Industry Advisory Committees.

Key Points: 
  • The committee assists the foundation in reviewing its scientific goals and grant applications, as well as providing strategic advice and support for its research programs and investments.
  • "The outstanding researchers on our advisory committees provide invaluable guidance and insight to help steer its programs toward success and impact."
  • "The Mark Foundation's funding of high-risk, high-impact research is essential in the quest to achieve real breakthroughs in cancer research," said Johanna Joyce, PhD.
  • "I am honored to join the Scientific Advisory Committee, to support the next generations of scientists and projects that will revolutionize treatments for patients."

Settlement Administrator Angeion Group Announces Proposed Settlements with Brown University, University of Chicago, the Trustees of Columbia University in the City of New York, Trustees of Dartmouth College, Duke University, Emory University, Northwestern

Retrieved on: 
Friday, March 29, 2024
Vanderbilt University, Tax, University, Action, Hearing, Summons, City, Emory University, University of Chicago, Class, Dartmouth College, Brown University, Fairness, Info, Massachusetts Institute of Technology, District court, Cornell University, Georgetown University, Defendant, Student, Rice, Settlement, Claim, California Institute of Technology, PC, University of Pennsylvania, Plaintiff, Trustee, School, University of Notre Dame, Columbia University, Johns Hopkins University, Pharmaceutical industry

PHILADELPHIA, March 29, 2024 /PRNewswire/ -- A federal court has preliminarily approved proposed settlements ("Settlements") with the following ten defendant universities: Brown University ("Brown"), University of Chicago ("Chicago"), the Trustees of Columbia University in the City of New York ("Columbia"), Trustees of Dartmouth College ("Dartmouth"), Duke University ("Duke"), Emory University ("Emory"), Northwestern University ("Northwestern"), William Marsh Rice University ("Rice"), Vanderbilt University ("Vanderbilt") and Yale University ("Yale"). The Court has also preliminarily approved a Settlement Class of students who attended the following seventeen schools (during certain time periods): Brown, California Institute of Technology, Chicago, Columbia, Cornell University, Dartmouth, Duke, Emory, Georgetown University, Johns Hopkins University, Massachusetts Institute of Technology, Northwestern, University of Notre Dame, University of Pennsylvania, Rice, Vanderbilt, and Yale (the "Defendants," or "Universities," or "Defendant Universities"). As a part of the Settlement, the Defendant Universities have agreed to make a settlement payment of $284 million and to provide certain additional information to Plaintiffs in this antitrust class action lawsuit called Henry, et al. v. Brown University, et al., 1:22-cv-00125, pending in the United States District Court for the Northern District of Illinois ("Action").

Key Points: 
  • PHILADELPHIA, March 29, 2024 /PRNewswire/ -- A federal court has preliminarily approved proposed settlements ("Settlements") with the following ten defendant universities: Brown University ("Brown"), University of Chicago ("Chicago"), the Trustees of Columbia University in the City of New York ("Columbia"), Trustees of Dartmouth College ("Dartmouth"), Duke University ("Duke"), Emory University ("Emory"), Northwestern University ("Northwestern"), William Marsh Rice University ("Rice"), Vanderbilt University ("Vanderbilt") and Yale University ("Yale").
  • v. Brown University, et al., 1:22-cv-00125, pending in the United States District Court for the Northern District of Illinois ("Action").
  • The Action was brought by certain students who attended the Universities while receiving partial need-based financial aid.
  • The Action alleges that the Universities conspired in violation of the federal antitrust laws regarding principles, formulas, and methods of determining financial aid.

Serum Detect Launches with Novel T-Cell Analysis Approach for Cancer Early Detection at AACR

Retrieved on: 
Thursday, March 28, 2024
Diagnosis, Lung cancer, Algorithm, University of Pennsylvania, Associate, Foundation Medicine, Biomedical Research, University, Research, DNA, Mortality, Cancer, Doctor of Philosophy, Gritstone bio, Serum, AACR, Neoplasm, TCR, Liquid biopsy, Blood, Antigen, Medical imaging

NEWTON, Mass., March 28, 2024 /PRNewswire/ -- Serum Detect , a cancer diagnostics company, is debuting a novel and promising approach for cancer early detection at the upcoming American Association for Cancer Research (AACR) conference.

Key Points: 
  • NEWTON, Mass., March 28, 2024 /PRNewswire/ -- Serum Detect , a cancer diagnostics company, is debuting a novel and promising approach for cancer early detection at the upcoming American Association for Cancer Research (AACR) conference.
  • The company is developing diagnostic tests, using standard liquid biopsy samples, that complement and enhance existing screening techniques for early detection of cancer.
  • "Detecting cancer early, before it has spread throughout the body, remains the primary way to achieve cancer cures.
  • Liquid biopsy, or the assessment of cancer through standard blood draws, is an important potential tool for cancer early detection.

Texas Cardiac Arrhythmia Institute at St. David's Medical Center to host international conference on complex cardiac arrhythmias

Retrieved on: 
Tuesday, March 26, 2024
Arrhythmia, American Medical Association, St Davids, University of Pennsylvania, Mount Sinai Hospital, MedStar Health, Patient, PFA, Electrophysiology, University, LAA, Medical Center, Cleveland Clinic, Atrial fibrillation, Ventricular tachycardia, Physician, Cardiac electrophysiology, Vancouver General Hospital, PRA

AUSTIN, Texas, March 26, 2024 /PRNewswire/ -- On April 18 and 19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center will host its seventh international symposium on complex arrhythmias, EPLive 2024.

Key Points: 
  • AUSTIN, Texas, March 26, 2024 /PRNewswire/ -- On April 18 and 19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center will host its seventh international symposium on complex arrhythmias, EPLive 2024.
  • Live cases, which are broadcast with expert commentary from the state-of-the-art Electrophysiology Center at St. David's Medical Center, will serve as the primary teaching tool.
  • The Texas Cardiac Arrhythmia Institute features the leading robotic electrophysiology center in North America.
  • The 72,000-square-foot center, which opened in 2019, includes six electrophysiology labs equipped with advanced technology for treatment of complex arrhythmias.

Texas Cardiac Arrhythmia Institute at St. David's Medical Center to host international conference on complex cardiac arrhythmias

Retrieved on: 
Tuesday, March 26, 2024
Arrhythmia, American Medical Association, St Davids, University of Pennsylvania, Mount Sinai Hospital, MedStar Health, Patient, PFA, Electrophysiology, University, LAA, Medical Center, Cleveland Clinic, Atrial fibrillation, Ventricular tachycardia, Physician, Cardiac electrophysiology, Vancouver General Hospital, PRA

AUSTIN, Texas, March 26, 2024 /PRNewswire/ -- On April 18 and 19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center will host its seventh international symposium on complex arrhythmias, EPLive 2024.

Key Points: 
  • AUSTIN, Texas, March 26, 2024 /PRNewswire/ -- On April 18 and 19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center will host its seventh international symposium on complex arrhythmias, EPLive 2024.
  • Live cases, which are broadcast with expert commentary from the state-of-the-art Electrophysiology Center at St. David's Medical Center, will serve as the primary teaching tool.
  • The Texas Cardiac Arrhythmia Institute features the leading robotic electrophysiology center in North America.
  • The 72,000-square-foot center, which opened in 2019, includes six electrophysiology labs equipped with advanced technology for treatment of complex arrhythmias.

The Inner Circle acknowledges Mr. Garry Pezzano as a Top Pinnacle Professional

Retrieved on: 
Tuesday, March 19, 2024
College, University of Pennsylvania, Harvard Business School, Business administration, Education, Genesis HealthCare, City, Health care, Speech–language pathology, University, Faculty, Ageing, International Council, Moving Forward, Commission, American Speech–Language–Hearing Association, Long-term care, Federal, Rutgers University, Master of Business Administration, EMBA, National Association, Multimedia, National academy, Inner circle, Nursing

MECHANICSBURG, Pa., March 19, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Mr. Garry Pezzano is acknowledged as a Top Pinnacle Professional for his contributions to evolving quality of care in post-acute aging services.

Key Points: 
  • MECHANICSBURG, Pa., March 19, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Mr. Garry Pezzano is acknowledged as a Top Pinnacle Professional for his contributions to evolving quality of care in post-acute aging services.
  • Mr. Pezzano pursued higher education at the College of New Jersey, earning a Bachelor of Science degree in Speech-Language Pathology.
  • Mr. Pezzano has enhanced clinical effectiveness across various roles, as he fosters innovation and driving progress during his tenure at Genesis Healthcare.
  • Notably, he has successfully guided organizations towards improved outcomes and operational efficiency through his effective leadership in driving change.